<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038727</url>
  </required_header>
  <id_info>
    <org_study_id>IND - DK048489</org_study_id>
    <secondary_id>U01DK048489</secondary_id>
    <nct_id>NCT00038727</nct_id>
    <nct_alias>NCT00353314</nct_alias>
  </id_info>
  <brief_title>Diabetes Prevention Program Outcomes Study</brief_title>
  <acronym>DPPOS</acronym>
  <official_title>Diabetes Prevention Program Outcomes Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indian Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Clinical Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an
      intensive lifestyle or metformin to prevent or delay the development of diabetes in a high
      risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of
      140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset
      by 58% and metformin reduced diabetes onset by 31%.

      DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable
      DPP participants. This group of participants is nearly 50% minority and represents the
      largest at risk population ever studied. Clinically important research questions remain that
      focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course
      of precisely known new onset diabetes, in particular regarding microvascular disease, CVD
      risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in
      minority populations.

      The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of
      the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and
      high degree of study retention and adherence (~85% of the DPPOS cohort continues to attend
      annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on
      cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and
      import.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current DPPOS Executive Summary and protocol, as well as DPPOS protocol and lifestyle
      manuals and publications are available at: http://www.dppos.org
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label phase for metformin</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Diabetes.</measure>
    <time_frame>Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).</time_frame>
    <description>Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level &gt;= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose &gt;= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Aggregate Microvascular Complication</measure>
    <time_frame>Outcomes were assessed from 2012-2013 (approximately 2 years).</time_frame>
    <description>Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (&lt;45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (&gt; 30mg/gm, confirmed).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cancer Except Non-melanoma Skin Cancer</measure>
    <time_frame>Outcomes were assessed from 1996-2020 (approximately 24 years).</time_frame>
    <description>All primary incident cancers except non-melanoma skin cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events (MACE): Myocardial Infarction (MI), Stroke, or Cardiovascular Death (CVD)</measure>
    <time_frame>Outcomes were assessed from 1996-2025 (approximately 29 years).</time_frame>
    <description>Defined as MI, stroke and CVD death. These outcomes were collected since randomization and adjudicated by an outcomes committee who are blinded to treatment assignment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subclinical Atherosclerosis</measure>
    <time_frame>Outcomes were assessed from 2012-2013 (approximately 2 years).</time_frame>
    <description>Measured using coronary artery calcification (CAC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>Outcomes were assessed in visit years starting in 2010, 2012, 2017, 2020.</time_frame>
    <description>Cognitive function defined as a composite measure constructed from tests of memory (English Spanish Verbal Learning Test) and executive function (word fluency and Digit Symbol Substitution Test ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Physical Performance Battery</measure>
    <time_frame>Outcomes were assessed in visit years starting in 2010, 2012, 2017, 2020.</time_frame>
    <description>Physical function is measured using the short physical performance battery (SPPB), which is comprised of measures of 1) time to walk 3-4 meters, 2) balance, i.e., side-by-side stand, semi-tandem stand, and tandem stand, and 3) repeated chair stands.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frailty</measure>
    <time_frame>Outcomes were assessed in visit years starting in 2010, 2012, 2017, 2020.</time_frame>
    <description>Description: The Cardiovascular Health Study Frailty score is based on 5 frailty characteristics: slow walking speed, low energy expenditure, exhaustion, weak grip strength, and unintentional weight loss.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2779</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Cancer</condition>
  <condition>CVD</condition>
  <arm_group>
    <arm_group_label>1 Original Lifestyle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Original Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Original Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>DPPOS Group Lifestyle</intervention_name>
    <description>Quarterly group lifestyle sessions</description>
    <arm_group_label>1 Original Lifestyle</arm_group_label>
    <arm_group_label>2 Original Metformin</arm_group_label>
    <arm_group_label>3 Original Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Administered as 850mg twice per day, masked in DPP and open label in DPPOS</description>
    <arm_group_label>2 Original Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>DPPOS Boost Lifestyle</intervention_name>
    <description>In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
    <arm_group_label>1 Original Lifestyle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive Lifestyle Group Session</intervention_name>
    <description>16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
    <arm_group_label>1 Original Lifestyle</arm_group_label>
    <arm_group_label>2 Original Metformin</arm_group_label>
    <arm_group_label>3 Original Placebo</arm_group_label>
    <other_name>Intensive lifestyle session (ILS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participation as a volunteer in the Diabetes Prevention Program (DPP).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Nathan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marinella Temprosa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Linder, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>NIDDK Project Scientist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kishore Gadde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Ehrmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Furlong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jefferson Medical College of Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Jablonski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald B Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen P Hazuda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dana Dabelea, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Medha Munshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kahn, MB, ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Dagogo-Jack, MD, MB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Health Science Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Molitch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Happy Araneta, PhD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F. Xavier Pi-Sunyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kieren J Mather, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michelle Magee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karol E Watson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angela Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherita Hill Golden, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David S Schade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jill Crandall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Venditti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjerie Mau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hawaii</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Knowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SW Indian Center, NIDDK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Santica M Marcovina, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David M Nathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>NIDDK Project Scientist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sunder Mudaliar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dppos.org</url>
    <description>Study website</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00004992</url>
    <description>Clinical trials.gov entry for DPP</description>
  </link>
  <reference>
    <citation>Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.</citation>
    <PMID>11832527</PMID>
  </reference>
  <results_reference>
    <citation>Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29. Erratum in: Lancet. 2009 Dec 19;374(9707):2054.</citation>
    <PMID>19878986</PMID>
  </results_reference>
  <results_reference>
    <citation>Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015 Nov;3(11):866-75. doi: 10.1016/S2213-8587(15)00291-0. Epub 2015 Sep 13.</citation>
    <PMID>26377054</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 4, 2002</study_first_submitted>
  <study_first_submitted_qc>June 4, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2002</study_first_posted>
  <results_first_submitted>February 21, 2017</results_first_submitted>
  <results_first_submitted_qc>September 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 24, 2017</results_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DPP</keyword>
  <keyword>IGT</keyword>
  <keyword>Prediabetes</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Macrovascular disease</keyword>
  <keyword>Microvascular disease</keyword>
  <keyword>Lifestyle</keyword>
  <keyword>Metformin</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repository</ipd_description>
    <ipd_time_frame>2002-2025</ipd_time_frame>
    <ipd_access_criteria>Instructions for access are detailed here: https://repository.niddk.nih.gov/pages/overall_instructions/</ipd_access_criteria>
    <ipd_url>https://repository.niddk.nih.gov/studies/dppos/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT00038727/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT00038727/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All surviving Diabetes Prevention Program (DPP) participants with consent were invited to enroll into DPPOS throughout the follow-up period. The majority of DPPOS participants were enrolled in 2002-2003.</recruitment_details>
      <pre_assignment_details>DPPOS covers 3 funding phases for the 3 study phases: DPPOS-1 (2002-2008), DPPOS-2 (2009-2014), DPPOS-3 (2015-2021). The groups are defined using the original randomized groups from DPP with recruitment period of 1996-1998.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Original Lifestyle</title>
          <description>Boost / Lifestyle, previously Intensive Lifestyle during the DPP
Group Lifestyle: Quarterly group lifestyle sessions
Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
        </group>
        <group group_id="P2">
          <title>2 Original Metformin</title>
          <description>Metformin / Lifestyle, previously the metformin treatment group during DPP
Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day</description>
        </group>
        <group group_id="P3">
          <title>3 Original Placebo</title>
          <description>Group Lifestyle, previously placebo treated participants during DPP
Group Lifestyle: Quarterly group lifestyle sessions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="916">Includes all enrollees from DPPOS 1-3</participants>
                <participants group_id="P2" count="927">Includes all enrollees from DPPOS 1-3</participants>
                <participants group_id="P3" count="936">Includes all enrollees from DPPOS 1-3</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>DPPOS Phase 1 Primary</title>
              <participants_list>
                <participants group_id="P1" count="910">As reported in the Lancet 2009</participants>
                <participants group_id="P2" count="924">As reported in the Lancet 2009</participants>
                <participants group_id="P3" count="932">As reported in the Lancet 2009</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>DPPOS Phase 2 Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="915">As reported in Lancet Diabetes and Endocrinology 2015</participants>
                <participants group_id="P2" count="926">As reported in Lancet Diabetes and Endocrinology 2015</participants>
                <participants group_id="P3" count="935">As reported in Lancet Diabetes and Endocrinology 2015</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>DPPOS Phase 2 Primary</title>
              <participants_list>
                <participants group_id="P1" count="751">As reported in Lancet Diabetes and Endocrinology 2015</participants>
                <participants group_id="P2" count="772">As reported in Lancet Diabetes and Endocrinology 2015</participants>
                <participants group_id="P3" count="780">As reported in Lancet Diabetes and Endocrinology 2015</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>DPPOS Phase 3 Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="916"/>
                <participants group_id="P2" count="927"/>
                <participants group_id="P3" count="936"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="916"/>
                <participants group_id="P2" count="927"/>
                <participants group_id="P3" count="936"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Original Lifestyle</title>
          <description>randomized to unmasked Intensive Lifestyle (ILS) during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2
DPPOS Group Lifestyle: Quarterly group lifestyle sessions
DPPOS Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
        </group>
        <group group_id="B2">
          <title>2 Original Metformin</title>
          <description>randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.
DPPOS Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day, masked in DPP and open label in DPPOS
Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
        </group>
        <group group_id="B3">
          <title>3 Original Placebo</title>
          <description>randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2
DPPOS Group Lifestyle: Quarterly group lifestyle sessions
Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="916"/>
            <count group_id="B2" value="927"/>
            <count group_id="B3" value="936"/>
            <count group_id="B4" value="2779"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>An additional 3 participants were enrolled after publication</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="915"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2778"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="11"/>
                    <measurement group_id="B2" value="54" spread="10"/>
                    <measurement group_id="B3" value="54" spread="10"/>
                    <measurement group_id="B4" value="54" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="916"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2779"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="11.1"/>
                    <measurement group_id="B2" value="51.3" spread="10.1"/>
                    <measurement group_id="B3" value="50.7" spread="10.0"/>
                    <measurement group_id="B4" value="51.1" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="916"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2779"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="624"/>
                    <measurement group_id="B2" value="620"/>
                    <measurement group_id="B3" value="645"/>
                    <measurement group_id="B4" value="1889"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="292"/>
                    <measurement group_id="B2" value="307"/>
                    <measurement group_id="B3" value="291"/>
                    <measurement group_id="B4" value="890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="916"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2779"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="544"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="596"/>
                    <measurement group_id="B2" value="628"/>
                    <measurement group_id="B3" value="612"/>
                    <measurement group_id="B4" value="1836"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="916"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2779"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="916"/>
                    <measurement group_id="B2" value="927"/>
                    <measurement group_id="B3" value="936"/>
                    <measurement group_id="B4" value="2779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="916"/>
                    <count group_id="B2" value="927"/>
                    <count group_id="B3" value="936"/>
                    <count group_id="B4" value="2779"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.7" spread="6.5"/>
                    <measurement group_id="B2" value="33.8" spread="6.5"/>
                    <measurement group_id="B3" value="34.0" spread="6.5"/>
                    <measurement group_id="B4" value="33.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Development of Diabetes.</title>
        <description>Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level &gt;= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose &gt;= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test).</description>
        <time_frame>Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Original Lifestyle</title>
            <description>Boost / Lifestyle, previously Intensive Lifestyle during the DPP
Group Lifestyle: Quarterly group lifestyle sessions
Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
          </group>
          <group group_id="O2">
            <title>2 Original Metformin</title>
            <description>Metformin / Lifestyle, previously the metformin treatment group during DPP
Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day</description>
          </group>
          <group group_id="O3">
            <title>3 Original Placebo</title>
            <description>Group Lifestyle, previously placebo treated participants during DPP
Group Lifestyle: Quarterly group lifestyle sessions</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Diabetes.</title>
          <description>Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level &gt;= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose &gt;= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test).</description>
          <units>diabetes incidence (cases per 100 person</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="916"/>
                <count group_id="O2" value="927"/>
                <count group_id="O3" value="936"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.8" upper_limit="5.8"/>
                    <measurement group_id="O2" value="6.4" lower_limit="5.9" upper_limit="7.1"/>
                    <measurement group_id="O3" value="7.8" lower_limit="7.2" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Aggregate Microvascular Complication</title>
        <description>Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (&lt;45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (&gt; 30mg/gm, confirmed).</description>
        <time_frame>Outcomes were assessed from 2012-2013 (approximately 2 years).</time_frame>
        <population>Number with microvascular outcome data and included in the primary outcome analysis</population>
        <group_list>
          <group group_id="O1">
            <title>1 Original Lifestyle</title>
            <description>Boost / Lifestyle, previously Intensive Lifestyle during the DPP
Group Lifestyle: Quarterly group lifestyle sessions
Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
          </group>
          <group group_id="O2">
            <title>2 Original Metformin</title>
            <description>Metformin / Lifestyle, previously the metformin treatment group during DPP
Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day</description>
          </group>
          <group group_id="O3">
            <title>3 Original Placebo</title>
            <description>Group Lifestyle, previously placebo treated participants during DPP
Group Lifestyle: Quarterly group lifestyle sessions</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Aggregate Microvascular Complication</title>
          <description>Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (&lt;45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (&gt; 30mg/gm, confirmed).</description>
          <population>Number with microvascular outcome data and included in the primary outcome analysis</population>
          <units>average percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="751"/>
                <count group_id="O2" value="772"/>
                <count group_id="O3" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="10.1" upper_limit="12.7"/>
                    <measurement group_id="O2" value="13" lower_limit="11.7" upper_limit="14.5"/>
                    <measurement group_id="O3" value="12.4" lower_limit="11.1" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Cancer Except Non-melanoma Skin Cancer</title>
        <description>All primary incident cancers except non-melanoma skin cancer</description>
        <time_frame>Outcomes were assessed from 1996-2020 (approximately 24 years).</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Adverse Cardiovascular Events (MACE): Myocardial Infarction (MI), Stroke, or Cardiovascular Death (CVD)</title>
        <description>Defined as MI, stroke and CVD death. These outcomes were collected since randomization and adjudicated by an outcomes committee who are blinded to treatment assignment.</description>
        <time_frame>Outcomes were assessed from 1996-2025 (approximately 29 years).</time_frame>
        <posting_date>06/2025</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subclinical Atherosclerosis</title>
        <description>Measured using coronary artery calcification (CAC).</description>
        <time_frame>Outcomes were assessed from 2012-2013 (approximately 2 years).</time_frame>
        <population>DPPOS Participants who met eligibility criteria and consented to have CAC measurements - by sex</population>
        <group_list>
          <group group_id="O1">
            <title>1 Original Lifestyle</title>
            <description>randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2
DPPOS Group Lifestyle: Quarterly group lifestyle sessions
DPPOS Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
          </group>
          <group group_id="O2">
            <title>2 Original Metformin</title>
            <description>randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.
DPPOS Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day, masked in DPP and open label in DPPOS
Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
          </group>
          <group group_id="O3">
            <title>3 Original Placebo</title>
            <description>randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2
DPPOS Group Lifestyle: Quarterly group lifestyle sessions
Intensive Lifestyle Group Session: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions</description>
          </group>
        </group_list>
        <measure>
          <title>Subclinical Atherosclerosis</title>
          <description>Measured using coronary artery calcification (CAC).</description>
          <population>DPPOS Participants who met eligibility criteria and consented to have CAC measurements - by sex</population>
          <units>CAC geometric mean in AU</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="701"/>
                <count group_id="O2" value="679"/>
                <count group_id="O3" value="681"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Men</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="468"/>
                    <count group_id="O2" value="464"/>
                    <count group_id="O3" value="486"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" lower_limit="45.4" upper_limit="108.2"/>
                    <measurement group_id="O2" value="40.2" lower_limit="26.1" upper_limit="61.9"/>
                    <measurement group_id="O3" value="63.7" lower_limit="41.3" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Women</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="215"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="4.1" upper_limit="8.8"/>
                    <measurement group_id="O2" value="6.1" lower_limit="4.2" upper_limit="9.0"/>
                    <measurement group_id="O3" value="5.3" lower_limit="3.6" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Function</title>
        <description>Cognitive function defined as a composite measure constructed from tests of memory (English Spanish Verbal Learning Test) and executive function (word fluency and Digit Symbol Substitution Test ).</description>
        <time_frame>Outcomes were assessed in visit years starting in 2010, 2012, 2017, 2020.</time_frame>
        <posting_date>07/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Physical Performance Battery</title>
        <description>Physical function is measured using the short physical performance battery (SPPB), which is comprised of measures of 1) time to walk 3-4 meters, 2) balance, i.e., side-by-side stand, semi-tandem stand, and tandem stand, and 3) repeated chair stands.</description>
        <time_frame>Outcomes were assessed in visit years starting in 2010, 2012, 2017, 2020.</time_frame>
        <posting_date>07/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frailty</title>
        <description>Description: The Cardiovascular Health Study Frailty score is based on 5 frailty characteristics: slow walking speed, low energy expenditure, exhaustion, weak grip strength, and unintentional weight loss.</description>
        <time_frame>Outcomes were assessed in visit years starting in 2010, 2012, 2017, 2020.</time_frame>
        <posting_date>07/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Until data lock of Jan 2014, average of 15 years of follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 Original Lifestyle</title>
          <description>Boost / Lifestyle, previously Intensive Lifestyle during the DPP
Group Lifestyle: Quarterly group lifestyle sessions
Boost Lifestyle: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
        </group>
        <group group_id="E2">
          <title>2 Original Metformin</title>
          <description>Metformin / Lifestyle, previously the metformin treatment group during DPP
Group Lifestyle: Quarterly group lifestyle sessions
Metformin: Administered as 850mg twice per day</description>
        </group>
        <group group_id="E3">
          <title>3 Original Placebo</title>
          <description>Group Lifestyle, previously placebo treated participants during DPP
Group Lifestyle: Quarterly group lifestyle sessions</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Costart dictionary</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="927"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="936"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="472" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="482" subjects_at_risk="927"/>
                <counts group_id="E3" subjects_affected="492" subjects_at_risk="936"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any SAE Report</sub_title>
                <counts group_id="E1" events="1099" subjects_affected="472" subjects_at_risk="916"/>
                <counts group_id="E2" events="1122" subjects_affected="482" subjects_at_risk="927"/>
                <counts group_id="E3" events="1103" subjects_affected="492" subjects_at_risk="936"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Costart dictionary</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="274" subjects_at_risk="927"/>
                <counts group_id="E3" subjects_affected="257" subjects_at_risk="936"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sprains and fractures requiring medical attention</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="916"/>
                <counts group_id="E2" subjects_affected="274" subjects_at_risk="927"/>
                <counts group_id="E3" subjects_affected="257" subjects_at_risk="936"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marinella Temprosa, PI of Coordinating Center</name_or_title>
      <organization>George Washington University</organization>
      <phone>3018819260</phone>
      <email>ella@bsc.gwu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

